Flow Markers Flashcards
Flow markers positive in AML typically
CD13, CD33, CD34, CD117
Monoblastic floe markers
CD11c, CD14, CD64
Erythroid differentiation markers
CD235 (glycophorin), CD36
Megakaryoblastic differentiation markers
CD41, CD61
Granulocytic differentiation markers
MPO, CD65
CLL flow markers
Positive: weak surface ig, CD5, CD23
Important- strong CD 43+, CD 200
Negative: 79b, FMC7-
Waldenstroms including genetic mutation
Positive: CD19, CD20, CD22 weak, CD25, CD79a and CD79b
Important: CD27, CD52
Equivocal: CD5, CD23
Negative: CD10, BCL6
MYD88 mutated 90%
CXCR4 30-40%
TP53 10%
Waldenstroms including genetic mutation
Positive: CD19, CD20, CD22 weak, CD25, CD79a and CD79b
Important: CD27, CD52
Equivocal: CD5, CD23
Negative: CD10, BCL6
MYD88 mutated 90%
CXCR4 30-40%
TP53 10%
Follicular lymphoma markers, cytogenetics and molecular
Positive: CD10, CD19, CD20, CD22, BCL2, BCL6
Variable: cyclin d1, CD43, k and l LV
CD21 and CD23 if nodular pattern
Negative: CD5, CD30
cytogenetics: characteristic t(14;18) IgH/BCL2 rearrangement
Molecular: KMT2D, EZH2, CARD11, RB1, FOXO1
Mantle cell flow, cytogenetics, molecular
Pos: CD19, CD20, CD22, CD79a, FMC7, BCL2
Weak: CD5
Negative: CD23
Cytogenetics: t(11;14) upregulated cyclinD1 (due to bcl1 dysregulation via IgH chr14)
Molecular: ATM, CCND1, TP53 and NOTCH1
SOX11 associated with indolent disease
DLBCL
pos: CD19, CD20, CD22, CD45 C-MYC (40% cut off), BCL2 (50%), BCL6 (GC MARKER)
Weak/variant: CD10 in GC, EBV
Negative: CD5, CD23, CD25, TdT
Cytogenetics/mol: BCL2, BCL6 translocations. MYC (Double or triple hit)
Primary CNS lymphoma
Pos: B cell markers, CD45, BCL2 and 6, MUM1, IRF4, MYC
Neg: TdT, CD10, CD30, CD38, CD138
Cyto/mol: MYD88 and BCL6 rearrangements/mutations
Primary mediating B cell lymphoma
Pos: CD19, CD20, CD22, 79B
variable: CD30
neg: EBV CD5 sIgM, CD15
Cytogenetics/molecular: 9q amplification of genes CD274 and PDCDILG2.
Dysregulation of JAKSTAT and NFkB pathway
Marginal zone flow
Pos: CD19, FMC7
weak/variable: CD103, MALT, BCL10
Neg: CD5, CD11c, CD23, CD25, BCL2
Splenic marginal zone flow and cytogenetics
Pos: CD19, 20, 79b, SmIg, FMC7, klc restricted
Weak/variable: CD23
Neg: CD5, CD10, 11c, CD25, CD103
Cytogenetics: 7q del, but highly varied
MALT cytogenetics
T(11;18), t(1;14) poor response to h pylori eradication
Burkitts
Pos: CD10, 19, 20, 22, BCL6, Smlg, 81, 38, BCL6, 79a
Neg: CD5, CD23 and TdT and BCL2
Ki67 >99%
Cytogenetics: t(8;14) mycigh, t(2;8)myc-llc t(14;18) myc-klc latter is poor prognosis
Peripheral t cell lymphoma NOS
Pos: CD4, 8 with TCR rearrangement and clonality
Neg: varies
Aberrant: CD5 and 7
Cyto/mol: loss 5q, 9q, 12q. Share gene expression as AITL. TCR rearrangements
AITL
Pos: CD4, 10, 21 if follicular cells present, BCL6, CXCL13, CXCR3
neg: reduced CD8 compared to CD4. 3 AND 7 may be negative
Cyto: additional X chr, trisomy 5, IDH2, TET2, IRF4
Anaplastic large cell lymphoma
Pos: EMA, TCR gebe rearrangements
variants: CD30 in alk+ve
Neg: CD3, EBV
Cyto: t(2;5) NPM1:ALK
Sezary/MFU
Pos: CD2,3,4,45RO and CD8. TCR beta gene rearrangements
Variant: CD30
Neg: CD7 and 26
Nk cell lymphoma
Pos: CD2, CD56, 3e EBV
Neg: no TCR rearrangement
Enteropathy associated t-Cell lymphoma (EATL)
Pos: CD8, CD56, 3e, TIA-1
neg: EBV, CD4 ABD CD5
cyto type 1: +9q or -16q. Associated with HLADQ2
type 2: +1q, 5q, 8q
Hepatosplenic t cell lymphoma
Pos: CD2, CD3, CD7, CD45, CD56 AND TIA-1
neg: CD4, CD5, CD8, EBV
Cyto: gamma-delta T cell receptor expression and isochrome 7q.
Alpha beta t cell receptor variant
Mutations activating JAK/STAT pathway
